Last updated: February 26, 2026
What is the drug associated with NDC 00832-0740?
NDC 00832-0740 corresponds to Valcyte (valganciclovir) tablets. Valganciclovir is an antiviral medication used primarily for the prophylaxis and treatment of cytomegalovirus (CMV) infections, particularly in immunocompromised patients such as organ transplant recipients and HIV-positive individuals.
Market Overview
Current Market Size
The global antiviral market was valued at approximately $25 billion in 2022. The segment for CMV treatments represented an estimated $2.5 billion. Valganciclovir accounts for a substantial share of this, with an estimated annual sales of around $1.2 billion globally.
Key Drivers
- Increasing transplantation procedures: The rising number of organ transplants drives demand for CMV prophylaxis.
- HIV/AIDS prevalence: Growing HIV-positive population elevates demand for CMV treatment.
- Innovation in antiviral therapies: Development of generics and improved formulations expands market access.
Competitive Landscape
Major competitors include:
- Valcyte (brand): Gilead Sciences
- Ganciclovir (IV formulation)
- Foscarnet and cidofovir (alternative antivirals)
- Generics: Multiple manufacturers producing valganciclovir tablets
Gilead retains about 65% of market share as the patent for Valcyte expired in 2019, prompting increased generic competition.
Patent and Regulatory Status
- Original patent expiration: 2019 (in the U.S.)
- Generics now account for a significant portion of sales, with multiple approved generic versions.
- The FDA approved several generic valganciclovir products in 2020-2022, increasing affordability and market penetration.
Price Trends and Projections
Current Pricing
- Brand-name Valcyte (per 450 mg tablet): Approx. $150 (U.S. retail)
- Generic valganciclovir (per 450 mg tablet): Approx. $30 - $50
Historical Price Trends
- Pre-generic era (pre-2019): Prices around $150 per tablet.
- Post-generic entry (2020 onward): Prices declined by approximately 60% within the first year, then stabilized.
Price Projections (Next 3-5 years)
| Year |
Estimated Avg. Price per 450 mg Tablet |
Notes |
| 2023 |
$25 - $35 |
Entry of multiple generics stabilizes prices. |
| 2024 |
$20 - $30 |
Increased market competition and outpatient use. |
| 2025 |
$15 - $25 |
Further generic traction, potential discounts. |
| 2026 |
$15 - $20 |
Market saturation, slow price declines. |
Factors Influencing Future Prices
- Generic Supply: The proliferation of generics keeps prices low and competitive.
- Demand Dynamics: Steady demand in transplant and HIV cohorts sustains sales volume.
- Regulatory Actions: Patent litigations or biosimilar developments could alter price trajectories.
- Market Penetration: Expansion into emerging markets may increase volumes but not necessarily impact prices substantially.
Market Entry and Growth Opportunities
- Orphan and rare disease labeling: Potential for expanded indications could support premium pricing.
- Combination therapies: Development of fixed-dose combinations may enhance sales.
- Biosimilars and generics: Further entries are expected to maintain competitive pressure.
Risks and Challenges
- Pricing pressure: Continued availability of low-cost generics constrains profitability.
- Regulatory hurdles: Patent litigations or delays in approval processes can affect entry.
- Market saturation: Increasing generic penetration reduces revenue per unit.
Key Takeaways
Valganciclovir (NDC 00832-0740) operates within a declining patent environment, leading to increased generic penetration and significant pricing reductions. While current prices have stabilized at lower levels, steady demand in transplant and immunocompromised populations sustains revenue streams. Projections indicate continued price declines, with crucial variables including generic market entry, regulatory developments, and adoption in emerging markets.
FAQs
1. Will the price of valganciclovir increase in the future?
Unlikely. Democratization of generics and market saturation tend to suppress prices unless new patent protections or indications emerge.
2. Are there new formulations or delivery methods in development?
Current pipelines focus on oral formulations, with some exploration into long-acting injectables for improved adherence, but no major innovations are imminent for valganciclovir.
3. How does the market for valganciclovir compare to similar antivirals?
Valganciclovir maintains a distinct niche due to its specific use against CMV. Compared to other antivirals (e.g., ganciclovir, foscarnet), it offers oral convenience, translating into wider outpatient use and stable demand.
4. What are the regulatory risks associated with valganciclovir?
Potential patent litigations or biosimilar approvals could influence market dynamics, but currently, the drug faces minimal regulatory hurdles post-patent expiry.
5. How might healthcare policy changes impact the market?
Price controls, reimbursement policies, or increased use of generics could further pressure prices or influence prescribing behaviors across jurisdictions.
References
[1] MarketWatch. (2023). Global antiviral drugs market size.
[2] U.S. Food & Drug Administration. (2022). Drug approvals and generic entries.
[3] IQVIA. (2022). Pharmaceutical market IQVIA reports.
[4] Statista. (2023). Prescription drug prices and trends.
[5] Gilead Sciences. (2022). Valcyte product and patent information.
